Evidence map›Paper›PMID 40531187›Full record

ArticleJournal of proteome research2025

The Effect of Preanalytical Conditions on Blood-Based Inflammation Biomarkers.

Thomas O'Donnell, Stephanie Weinstein, Yukiko Yano, Paul Albert, Amanda Black, Michelle Brotzman, Norma Diaz-Mayoral, Alaina Shreves, Nicole Gerlanc, Kathleen Wyatt and 3 more

Abstract read
In one paragraph

Article in Journal of proteome research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Thomas O'DonnellDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland 20850, United States.ORCID 0009-0004-6123-1782
Stephanie WeinsteinDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland 20850, United States.
Yukiko YanoDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland 20850, United States.
Paul AlbertDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland 20850, United States.
Amanda BlackDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland 20850, United States.
Michelle BrotzmanDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland 20850, United States.
Norma Diaz-MayoralBioProcessing Laboratory, Frederick National Laboratory for Cancer Research, Frederick, Maryland 21701, United States.
Alaina ShrevesDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland 20850, United States.
Nicole GerlancDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland 20850, United States.
Kathleen WyattDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland 20850, United States.
Mia M GaudetDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland 20850, United States.
Christian AbnetDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland 20850, United States.
Nicolas WentzensenDivision of Cancer Epidemiology and Genetics, National Cancer Institute, National Institutes of Health, Rockville, Maryland 20850, United States.

Funding

WORK ORDER 126643 B539 EXPAND IC SUITE75N91019D00024 · NIAID · LEIDOS BIOMEDICAL RESEARCH, INC. · PI BRISCOE, LYNN · 2019 to 2025
$3932.6M
Cohort and Biobank DevelopmentZICCP010226 · NCI · DIVISION OF CANCER EPIDEMIOLOGY AND GENETICS · PI KRAFT, PETER · 2014 to 2025
$133.4M
Intramural NIH HHS ZIC CP010226NIH HHS 75N91019D00024
6 · The paper itself

Abstract

Blood-based inflammation biomarkers have potential for diagnostic, prognostic, and predictive testing, but preanalytical processing conditions can affect biomarker levels. We investigated how needle-to-freezer time, centrifugation timing, and tube types influence inflammation biomarkers. Twenty subjects donated 21 different blood samples in collection tubes, including plasma and serum types. Ninety-two biomarkers from each sample were analyzed using the Olink Target 96 Inflammation panel. We compared biomarker concentrations across different preanalytical variables to a reference standard tube. Intraclass, Pearson, and Spearman's correlation coefficients were calculated. We also assessed the impact of these conditions on age-related associations with biomarkers. Across the preprocessing protocol/blood matrix combinations, 38%-83%, 50%-87%, and 47%-79% of proteins showed good to excellent correlations in intraclass, Pearson, and Spearman analyses, respectively. Eighteen proteins differed by >0.5 NPX units between test and reference protocols. Among 30 comparisons of age-related biomarker associations showing

Indexed as

BiomarkersBlood ProteinsBlood Specimen CollectionInflammationAdultAgedFemaleHumansMaleMiddle AgedBiomarkersBlood Proteinsbiological samplebiomarkerblood samplecancerConnect Cancer Prevention Studyepidemiologic studyimmunoassayinflammationOlinkpreanalytical variables

Identifiers

PMID40531187
PMCPMC13339302

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.